Michael Magro

ORCID: 0000-0002-0581-3532
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Coronary Interventions and Diagnostics
  • Cardiac Imaging and Diagnostics
  • Acute Myocardial Infarction Research
  • Antiplatelet Therapy and Cardiovascular Diseases
  • Cardiac Arrest and Resuscitation
  • Cardiac Valve Diseases and Treatments
  • Cerebrovascular and Carotid Artery Diseases
  • Cardiac, Anesthesia and Surgical Outcomes
  • Atrial Fibrillation Management and Outcomes
  • Mechanical Circulatory Support Devices
  • Cardiac tumors and thrombi
  • Cardiac Health and Mental Health
  • Cardiovascular Function and Risk Factors
  • Endometriosis Research and Treatment
  • Peripheral Artery Disease Management
  • Optical Coherence Tomography Applications
  • Cardiac and Coronary Surgery Techniques
  • Heart Rate Variability and Autonomic Control
  • Uterine Myomas and Treatments
  • Maternal and fetal healthcare
  • Lipoproteins and Cardiovascular Health
  • Heart Failure Treatment and Management
  • Maternal and Perinatal Health Interventions
  • Ectopic Pregnancy Diagnosis and Management
  • Cardiovascular Disease and Adiposity

Barking, Havering And Redbridge University Hospitals NHS Trust
2019-2025

Elisabeth-TweeSteden Ziekenhuis
2017-2024

Hospital Universitario Ramón y Cajal
2024

Queen's Medical Center
2023

Queen's Hospital
2022-2023

HSBC Holdings
2023

Hospital Universitario de Guadalajara
2023

Queen's Hospital
2012-2023

Baim Institute for Clinical Research
2021

Tergooi
2020

Background— Early-generation drug-eluting stents releasing sirolimus (SES) or paclitaxel (PES) are associated with increased risk of very late stent thrombosis occurring >1 year after implantation. It is unknown whether the persists newer-generation everolimus-eluting (EES). Methods and Results— We assessed in a cohort 12 339 patients unrestricted use (3819 SES, 4308 PES, 4212 EES). Results incidence rates per 100 person-years inverse probability treatment weighting to adjust for group...

10.1161/circulationaha.111.058560 article EN Circulation 2012-02-02

Abstract Aims The aim of this study was to understand the impact optical coherence tomography (OCT)-detected thin-cap fibroatheroma (TCFA) on clinical outcomes diabetes mellitus (DM) patients with fractional flow reserve (FFR)-negative lesions. Methods and results COMBINE OCT-FFR a prospective, double-blind, international, natural history study. After FFR assessment, revascularization FFR-positive lesions, ≥1 FFR-negative lesions (target lesions) were classified in two groups based presence...

10.1093/eurheartj/ehab433 article EN European Heart Journal 2021-06-25

Invasive imaging modalities have shown restoration of vasomotion, prevention restenosis and, most importantly, increase in lumen area between six months and two years after first-generation everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) implantation. Our aim was to assess whether these positive findings were sustained the long term.Patients included ABSORB cohort A from Thoraxcenter Rotterdam underwent coronary catheterisation including angiography, intravascular ultrasound...

10.4244/eijy14m10_12 article EN EuroIntervention 2016-01-20

<h3>Importance</h3> Ischemic heart disease is a common cause of cardiac arrest. However, randomized data on long-term clinical outcomes immediate coronary angiography and percutaneous intervention (PCI) in patients successfully resuscitated from arrest the absence ST segment elevation myocardial infarction (STEMI) are lacking. <h3>Objective</h3> To determine whether improves at 1 year after without signs STEMI, compared with delayed strategy. <h3>Design, Setting, Participants</h3> A...

10.1001/jamacardio.2020.3670 article EN JAMA Cardiology 2020-09-02

To assess whether the obesity paradox persists in long term and to study effect of optimal medical treatment on this phenomenon.A retrospective cohort study.A tertiary care centre Rotterdam.From January 2000 December 2005, 6332 patients undergoing percutaneous coronary intervention for artery disease were categorised into underweight (body mass index (BMI)<18.5), normal (18.5-24.9), overweight (25-29.9) obese (>30).Mortality.Cardiac death non-fatal myocardial infarction.Optimal was more...

10.1136/bmjopen-2011-000535 article EN cc-by-nc BMJ Open 2012-01-01

Autopsy studies have established that thin-cap fibroatheromas (TCFAs) are the most frequent cause of fatal coronary events. In living patients, optical coherence tomography (OCT) has sufficient resolution to accurately differentiate TCFA from thick-cap fibroatheroma (ThCFA) and not lipid rich plaque (non-LRP). However, impact OCT-detected phenotype nonischemic lesions on future adverse events remains unknown. Therefore, we studied natural history TCFA, ThCFA, non-LRP in patients enrolled...

10.1161/circinterventions.121.011728 article EN Circulation Cardiovascular Interventions 2022-05-01

BACKGROUND: Despite fractional flow reserve (FFR)–guided deferral of revascularization, recurrent events in patients with diabetes or after myocardial infarction remain common. This study aimed to assess the association between FFR-negative but high-risk nonculprit lesions and clinical outcomes. METHODS: is a patient-level pooled analysis prospective natural-history COMBINE (OCT-FFR) (Optical Coherence Tomography Morphologic Fractional Flow Reserve Assessment Diabetes Mellitus Patients)...

10.1161/circinterventions.124.014667 article EN Circulation Cardiovascular Interventions 2025-01-22

Abstract Background DACC wound dressings, in this case Leukomed® Sorbact®, work by permanently binding bacteria, thereby reducing the bacterial load at site during healing. Current rates of surgical infections (SSI) after Caesarean section (CS) range from 3%–20%, however reporting is not mandatory UK and true scale problem unknown. A CS second most performed procedure EU increasing an alarming rate. Inevitability, will increase occurrence SSI, associated antibiotic prescribing burden,...

10.1093/jacamr/dlae217.019 article EN cc-by JAC-Antimicrobial Resistance 2025-01-01

Abstract Aims Surgical Site Infections (SSI) are one of the most common complications after a caesarean with significant morbidity. With rising section rates internationally, caused by post operative surgical site infections will increase. The Evidence suggests that using bacteria binding Leukomed® Sorbact® (Essity) wound dressing to reduce bacterial colonisation, SSI can be reduced caesarean. Barking, Havering &amp; Redbridge University Hospitals NHS Trust, London, UK (BHRUT) maternity unit...

10.1093/bjs/znaf024.017 article EN British journal of surgery 2025-02-01

Two-dimensional (2D) frequency domain optical coherence tomography (FD-OCT) has enhanced our understanding of coronary atherosclerotic disease and is increasingly being used in conventional percutaneous intervention (PCI) to elucidate mechanisms improve complex anatomy. Since the first report three-dimensional (3D) OCT applied human vessels,1 technology rapidly progressed.2–10 Currently, main limitation this need for off-line creation 3D reconstructions—prototypes current generation ‘real...

10.1093/eurheartj/ehr409 article EN European Heart Journal 2011-11-21

Background: Invasive imaging modalities have shown restoration of vasomotion, prevention restenosis and most importantly increase in lumen area between 6-months 2-years after first-generation everolimus-eluting bioresorbable vascular scaffold (Absorb BVS) implantation. Our aim was to assess whether these positive findings were sustained the long-term.

10.1093/eurheartj/eht310.p5488 article EN European Heart Journal 2013-08-02

Acute coronary syndromes (ACS) are often caused by rupture of non-flow limiting "vulnerable" atherosclerotic plaque, characterised a large necrotic core pool and thin, inflamed fibrous cap that unidentifiable with diagnostic angiography. The implementation novel invasive imaging modalities, such as intravascular ultrasound-virtual histology (IVUS-VH) near-infrared spectroscopy (NIRS), could help identify high-risk patients who in need aggressive medical therapy. intake high dose rosuvastatin...

10.4244/eijv8i2a37 article EN EuroIntervention 2012-06-01
Coming Soon ...